Researchers have reported a significant advance in the quest for an HIV vaccine, using a novel strategy to train the immune system to produce broadly neutralizing antibodies (bnAbs) in primates. The study, published in the journal Science on July 18, 2026, demonstrates that a series of immunogens can guide B cells to develop into cells that produce bnAbs capable of neutralizing multiple strains of HIV.
The approach, known as 'germline targeting,' involves a sequence of engineered proteins designed to activate rare precursor B cells and steer them through a process of mutation and selection. In the primate study, led by researchers at the Scripps Research Institute and the International AIDS Vaccine Initiative (IAVI), the vaccine regimen induced bnAbs in 80% of the vaccinated animals after a booster shot.
This result builds on earlier work in humans that showed the first step of the strategy was safe and effective at activating the desired B cell precursors. The new findings in primates provide the strongest evidence yet that the full multi-step process can produce bnAbs, which have been a major goal of HIV vaccine research for decades.
Dr. William Schief, a professor at Scripps Research and senior author of the study, said, 'This is a major milestone. We have shown that we can design a vaccine to elicit broadly neutralizing antibodies against HIV in a primate model, which gives us confidence that a similar approach could work in humans.' The next step will be to test the full regimen in human clinical trials, which are expected to begin in 2027.
The development is particularly notable because HIV mutates rapidly, making it difficult for the immune system to mount an effective response. If successful in humans, this vaccine could provide long-lasting protection against the virus, which infects about 1.3 million people each year globally.
